Histone deacetylase inhibition in the treatment of heart disease

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Epigenetics

Background:

• Chromatin remodeling, particularly histone acetylation, regulates gene expression in the heart.
• Histone deacetylase (HDAC) inhibitors are emerging pharmacologic agents with potential in various diseases.
• Preclinical studies indicate HDAC inhibition may prevent adverse cardiac remodeling.

Purpose of the Study:

• To review the mechanisms of action of HDAC inhibitors in cardiac tissue.
• To summarize current data on the effects of HDAC inhibitors on cardiac remodeling and function in disease contexts.

Main Methods:

• Review of preclinical studies and ongoing clinical trials.
• Analysis of molecular mechanisms underlying HDAC inhibition in cardiomyocytes.
• Synthesis of data on functional outcomes in models of cardiac disease.

Main Results:

• HDAC inhibition can blunt pathological cardiac myocyte growth.
• Emerging data suggest potential therapeutic benefits in cardiovascular disease.
• Compounds targeting HDACs are under investigation for multiple conditions.

Conclusions:

• HDAC inhibitors represent a promising therapeutic strategy for heart disease.
• Understanding their mechanisms is crucial for clinical application.
• Further research is warranted to establish efficacy and safety in cardiovascular patients.